Sequential combination with ropeginterferon alfa-2b and anti-PD-1 treatment as adjuvant therapy in HBV-related HCC: a phase 1 dose escalation trial
This phase I trial supports the safety and clinical efficacy of sequential treatment with ropeg and nivolumab in post-resection HBV-related HCC. This regimen holds promise for further adjuvant therapy trials in HCC, both HBV-related and other types.
Authors
- Albert Qin (ORCID: https://orcid.org/0000-0001-7610-084X)
- Chan‐Yen Tsai (ORCID: https://orcid.org/0000-0001-7772-6967)
- Ming‐Chih Ho (ORCID: https://orcid.org/0000-0003-3660-1062)
- Pei‐Jer Chen (ORCID: https://orcid.org/0000-0001-8316-3785)
- Chun‐Jen Liu (ORCID: https://orcid.org/0000-0002-6202-0993)
Institutions
- National Taiwan University (TW)
- National Taiwan University Hospital (TW)
Publication Details
- Journal
- Hepatology International
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1007/s12072-025-10824-4
- Citations
- 7
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 9.25